|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
ATE249840T1
(de)
|
1991-12-13 |
2003-10-15 |
Xoma Corp |
Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
DK1180123T3
(da)
|
1999-05-27 |
2008-10-13 |
Us Gov Health & Human Serv |
Immunkonjugater, der har höj bindingsaffinitet
|
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
WO2001062895A2
(en)
|
2000-02-24 |
2001-08-30 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
US6822082B2
(en)
|
2000-06-30 |
2004-11-23 |
Zymogenetics, Inc. |
Polynucleotides for mammalian secreted protein, Z1055G2P
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
EP1474451A2
(en)
|
2002-02-13 |
2004-11-10 |
Micromet AG |
De-immunized (poly)peptide constructs
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
CA2505325C
(en)
|
2002-11-08 |
2014-02-25 |
Ablynx N.V. |
Stabilized single domain antibodies
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
US7251470B2
(en)
|
2003-06-25 |
2007-07-31 |
Nokia Corporation |
Emergency response system with personal emergency device
|
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
US20050048617A1
(en)
|
2003-08-18 |
2005-03-03 |
Medimmune, Inc. |
Humanization of antibodies
|
|
CA2537055A1
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
DK1673398T3
(da)
|
2003-10-16 |
2011-04-18 |
Micromet Ag |
Multispecifikke, deimmuniserede CD3-bindere
|
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
WO2006018833A2
(en)
|
2004-08-16 |
2006-02-23 |
Tadiran Spectralink Ltd. |
A wearable device, system and method for measuring a pulse while a user is in motion
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EP2322560B1
(en)
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
WO2006124641A2
(en)
|
2005-05-12 |
2006-11-23 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Anti-mesothelin antibodies useful for immunological assays
|
|
CA2618482C
(en)
|
2005-08-19 |
2014-10-07 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
SI2215121T1
(sl)
|
2007-11-26 |
2016-06-30 |
Bayer Intellectual Property Gmbh |
Protitelesa anti-mezotelin in njihova uporaba
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
KR20090092900A
(ko)
|
2008-02-28 |
2009-09-02 |
신준호 |
어린이 및 노약자 안전보호시스템
|
|
US20090322513A1
(en)
|
2008-06-27 |
2009-12-31 |
Franklin Dun-Jen Hwang |
Medical emergency alert system and method
|
|
PL3006459T3
(pl)
|
2008-08-26 |
2022-01-17 |
City Of Hope |
Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
|
|
SG194399A1
(en)
|
2008-10-01 |
2013-11-29 |
Amgen Res Munich Gmbh |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
WO2010052014A1
(en)
|
2008-11-07 |
2010-05-14 |
Micromet Ag |
Treatment of acute lymphoblastic leukemia
|
|
MX2011009430A
(es)
|
2009-03-10 |
2011-11-18 |
Biogen Idec Inc |
Anticuerpos anti-bcma.
|
|
EP2421899B1
(en)
|
2009-04-23 |
2016-06-08 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-human ror1 antibodies
|
|
EP2258719A1
(en)
|
2009-05-19 |
2010-12-08 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Multiple target T cell receptor
|
|
EP3260092A1
(en)
|
2009-10-23 |
2017-12-27 |
Nexisvision, Inc. |
Corneal denervation for treatment of ocular pain
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
EP2361936B1
(en)
|
2010-02-25 |
2016-04-20 |
Affimed GmbH |
Antigen-binding molecule and uses thereof
|
|
CA3002192C
(en)
|
2010-03-26 |
2023-03-07 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
US10357577B2
(en)
|
2010-07-16 |
2019-07-23 |
Auckland Uniservices Limited |
Bacterial nitroreductase enzymes and methods relating thereto
|
|
US9493740B2
(en)
|
2010-09-08 |
2016-11-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered GD2-specific T cells
|
|
AU2011322581B2
(en)
|
2010-10-27 |
2015-04-23 |
Amgen Research (Munich) Gmbh |
Means and methods for treating DLBCL
|
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
AU2011336650B2
(en)
|
2010-12-01 |
2016-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ROR1 antibodies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
US8911732B2
(en)
|
2010-12-20 |
2014-12-16 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
PT2663579T
(pt)
|
2011-01-14 |
2017-07-28 |
Univ California |
Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
|
|
CN103442768A
(zh)
|
2011-01-18 |
2013-12-11 |
宾夕法尼亚大学董事会 |
治疗癌的组合物和方法
|
|
KR101551555B1
(ko)
|
2011-03-17 |
2015-09-08 |
밀테니 비오텍 게앰베하 |
Tcr 알파/베타가 고갈된 세포 제제
|
|
ES2696000T3
(es)
|
2011-04-08 |
2019-01-11 |
Us Health |
Receptores de antígenos quiméricos anti-variante III de receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US9447194B2
(en)
|
2012-02-13 |
2016-09-20 |
Seattle Children's Hospital |
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
|
|
KR20140127816A
(ko)
|
2012-02-22 |
2014-11-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
RU2650805C2
(ru)
|
2012-04-11 |
2018-04-17 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
|
|
US20130280220A1
(en)
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
|
WO2013176915A1
(en)
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
|
EA028988B1
(ru)
|
2012-07-13 |
2018-01-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Способ in vitro анализа культуры генетически модифицированных т-клеток для детекции загрязнения
|
|
MX380109B
(es)
|
2012-08-20 |
2025-03-12 |
Fred Hutchinson Cancer Center Star |
Metodo y composiciones para inmunoterapia celular.
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
MX370148B
(es)
|
2012-10-02 |
2019-12-03 |
Memorial Sloan Kettering Cancer Center |
Composiciones y su uso para inmunoterapia.
|
|
CA2892059C
(en)
|
2012-11-21 |
2023-02-14 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
|
JP2016507523A
(ja)
|
2013-02-05 |
2016-03-10 |
エンクマフ アーゲー |
ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
|
|
AU2014214850C1
(en)
|
2013-02-06 |
2018-12-06 |
Celgene Corporation |
Modified T lymphocytes having improved specificity
|
|
KR102064230B1
(ko)
|
2013-02-15 |
2020-01-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
UY35340A
(es)
|
2013-02-20 |
2014-09-30 |
Novartis Ag |
Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
|
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
IL298125A
(en)
|
2013-02-26 |
2023-01-01 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
ES2750550T3
(es)
|
2013-03-01 |
2020-03-26 |
Univ Minnesota |
Corrección de gen a base de TALEN
|
|
AU2014225788B2
(en)
|
2013-03-05 |
2018-03-29 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
HK1220205A1
(zh)
|
2013-03-15 |
2017-04-28 |
Celgene Corporation |
修饰的t淋巴细胞
|
|
EP4098275A1
(en)
|
2013-03-15 |
2022-12-07 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
WO2014165707A2
(en)
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
MX374681B
(es)
|
2013-05-13 |
2025-03-06 |
Cellectis |
Receptor quimérico de antígeno específico para cd19 y sus usos.
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
HK1223943A1
(zh)
|
2013-05-24 |
2017-08-11 |
Board Of Regents, The University Of Texas System |
嵌合的靶向抗原受体的单克隆抗体
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
MX2016000272A
(es)
|
2013-07-12 |
2016-08-03 |
Zymeworks Inc |
Construcciones de unión a los antígenos cd19 y cd3 biespecificos.
|
|
US9951118B2
(en)
|
2013-08-02 |
2018-04-24 |
The Regents Of The University Of California |
Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
|
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN105829349B
(zh)
|
2013-10-15 |
2023-02-03 |
斯克利普斯研究所 |
肽嵌合抗原受体t细胞开关和其用途
|
|
WO2015057852A1
(en)
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
|
PL3083671T3
(pl)
|
2013-12-20 |
2021-03-22 |
Fred Hutchinson Cancer Center |
Znakowane chimeryczne cząsteczki efektorowe i ich receptory
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
WO2015103072A1
(en)
|
2013-12-30 |
2015-07-09 |
Epimab Biotherapeutics |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
ES2701846T3
(es)
|
2014-01-14 |
2019-02-26 |
Cellectis |
Receptor de antígeno quimérico que usa dominios de reconocimiento de antígenos derivados de pez cartilaginoso
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
EP3097123A1
(en)
|
2014-01-24 |
2016-11-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
|
|
ES2989838T3
(es)
|
2014-02-04 |
2024-11-27 |
The United States Of America As Represented Bythe Sec Dep Of Health And Humanservices |
Métodos para producir células T autólogas útiles para tratar malignidades de células B y otros cánceres y composiciones de las mismas
|
|
WO2015123642A1
(en)
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
PT3105317T
(pt)
|
2014-02-14 |
2019-02-27 |
Cellectis |
Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas
|
|
WO2015124715A1
(en)
|
2014-02-21 |
2015-08-27 |
Cellectis |
Method for in situ inhibition of regulatory t cells
|
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3119425B1
(en)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
JP6698546B2
(ja)
*
|
2014-04-14 |
2020-05-27 |
セレクティスＣｅｌｌｅｃｔｉｓ |
癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
|
|
EP3134095B1
(en)
|
2014-04-25 |
2020-04-22 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
WO2015177349A1
(en)
|
2014-05-23 |
2015-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- egfr conformational single domain antibodies and uses thereof
|
|
CN111394317B
(zh)
*
|
2014-06-06 |
2024-07-12 |
2赛文缇生物公司 |
改善的t细胞组合物
|
|
EP3685842B1
(en)
|
2014-06-06 |
2022-08-31 |
Memorial Sloan-Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
|
MY181834A
(en)
*
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US20170226216A1
(en)
*
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
MX367787B
(es)
|
2014-07-29 |
2019-09-06 |
Cellectis |
Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US9994817B2
(en)
|
2014-08-07 |
2018-06-12 |
Northwestern University |
Use of ligands for the programmed cell death receptor conjugated to solid supports for cultivating human regulatory T cells
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
JP6945444B2
(ja)
|
2014-08-08 |
2021-10-06 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
高親和性ｐｄ−１薬剤とその使用方法
|
|
SG11201701111SA
(en)
|
2014-08-12 |
2017-03-30 |
Anthrogenesis Corp |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
DK4074735T3
(da)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
GB201415347D0
(en)
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
|
SG11201701775VA
(en)
|
2014-09-09 |
2017-04-27 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
ES2738705T3
(es)
|
2014-09-19 |
2020-01-24 |
Hope City |
Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
|
|
WO2016054520A2
(en)
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
|
EP3204491A1
(en)
|
2014-10-07 |
2017-08-16 |
Cellectis |
Method for modulating car-induced immune cells activity
|
|
AU2015336029B2
(en)
|
2014-10-20 |
2021-07-22 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
|
HK1243333A1
(zh)
|
2014-10-31 |
2018-07-13 |
The Trustees Of The University Of Pennsylvania |
用於修饰的t细胞的方法和组合物
|
|
EP3215139B1
(en)
|
2014-11-03 |
2020-08-19 |
Cerus Corporation |
Compositions and methods for improved car-t cell therapies
|
|
PL3757206T3
(pl)
|
2014-11-05 |
2024-07-08 |
Juno Therapeutics, Inc. |
Sposoby transdukcji i przetwarzania komórek
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
US11266739B2
(en)
|
2014-12-03 |
2022-03-08 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SI3227339T1
(sl)
|
2014-12-05 |
2022-02-28 |
Memorial Sloan-Kettering Cancer Center |
Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
|
|
SG11201704549UA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
CN113388036A
(zh)
|
2014-12-05 |
2021-09-14 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的抗体及其用途
|
|
AU2015367317A1
(en)
|
2014-12-17 |
2017-06-01 |
Cellectis |
Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
|
|
EP3037170A1
(en)
|
2014-12-27 |
2016-06-29 |
Miltenyi Biotec GmbH |
Multisort cell separation method
|
|
KR20250075716A
(ko)
|
2014-12-29 |
2025-05-28 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
|
BR112017015136A2
(pt)
|
2015-01-14 |
2018-01-30 |
Compass Therapeutics Llc |
polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
GB201501175D0
(en)
|
2015-01-23 |
2015-03-11 |
Univ Oslo Hf |
A universal T-cell for personalised medicine
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016127043A1
(en)
|
2015-02-05 |
2016-08-11 |
Stc.Unm |
Anti-pre-bcr antagonists and methods
|
|
US20180016352A1
(en)
|
2015-02-05 |
2018-01-18 |
The University Of Queensland |
Targeting constructs for delivery of payloads
|
|
US20160228547A1
(en)
|
2015-02-06 |
2016-08-11 |
Batu Biologics, Inc. |
Chimeric antigen receptor targeting of tumor endothelium
|
|
KR102607152B1
(ko)
|
2015-02-12 |
2023-11-27 |
유니버시티 헬스 네트워크 |
키메라 항원 수용체
|
|
US20160237407A1
(en)
|
2015-02-17 |
2016-08-18 |
Batu Biologics, Inc. |
Universal donor chimeric antigen receptor cells
|
|
AU2016221305B2
(en)
|
2015-02-18 |
2021-05-27 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
JP6784687B2
(ja)
|
2015-02-24 |
2020-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
結合誘発型転写スイッチ及びその使用方法
|
|
EP3089761B1
(en)
|
2015-03-02 |
2019-06-12 |
Innovative Cellular Therapeutics Co., Ltd. |
Reducing immune tolerance induced by pd l1
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA2981304C
(en)
|
2015-04-02 |
2024-01-02 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/hvem proteins and methods of use thereof
|
|
PT3298033T
(pt)
|
2015-05-18 |
2020-09-22 |
Tcr2 Therapeutics Inc |
Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
|
|
CA2989949A1
(en)
|
2015-06-19 |
2016-12-22 |
Sebastian KOBOLD |
Pd-1-cd28 fusion proteins and their use in medicine
|
|
AU2016333898B2
(en)
|
2015-10-05 |
2020-11-12 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
|
|
EP4643874A2
(en)
|
2015-12-22 |
2025-11-05 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
SG10201912489QA
(en)
|
2016-04-01 |
2020-02-27 |
Kite Pharma Inc |
Chimeric antigen and t cell receptors and methods of use
|
|
EP4371570A3
(en)
|
2016-06-08 |
2024-07-17 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP2020513754A
(ja)
|
2016-12-21 |
2020-05-21 |
ティーシーアール２ セラピューティクス インク． |
がん治療用に操作されたｔ細胞
|
|
WO2018200583A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
|
US20210079057A1
(en)
|
2017-06-13 |
2021-03-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP2021515598A
(ja)
|
2018-03-09 |
2021-06-24 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法
|
|
WO2019222275A2
(en)
|
2018-05-14 |
2019-11-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using inducible fusion proteins
|
|
CN113039197A
(zh)
|
2018-07-26 |
2021-06-25 |
T细胞受体治疗公司 |
使用靶特异性融合蛋白进行tcr重编程的组合物和方法
|
|
EP3844192A1
(en)
|
2018-08-30 |
2021-07-07 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|